Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis

Background Patients with distributive shock who are unresponsive to traditional vasopressors are commonly considered to have severe distributive shock and are at high mortality risk. Here, we assess the cost-effectiveness of adding angiotensin II to the standard of care (SOC) for severe distributive shock in the US critical care setting from a US payer perspective. Methods Short-term mortality outcomes were based on 28-day survival rates from...